1. 401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. (9th November 2020) Authors: Sharma, Manish; Dumbrava, Ecaterina Ileana; Carvajal, Richard; Catenacci, Daniel; Emens, Leisha; Hanna, Glenn; Juric, Dejan; Kang, Yoon-Koo; Lee, Jeeyun; Lee, Keun-Wook; Li, Bob; Moore, Kathleen; Pegram, Mark; Pohlmann, Paula; Rasco, Drew; Spira, Alexander; Tan, Antoinette; Wang, Ding; Ackerman, ... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A244 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. (9th November 2020) Authors: Sharma, Manish; Dumbrava, Ecaterina Ileana; Carvajal, Richard; Catenacci, Daniel; Emens, Leisha; Hanna, Glenn; Juric, Dejan; Kang, Yoon-Koo; Lee, Jeeyun; Lee, Keun-Wook; Li, Bob; Moore, Kathleen; Pegram, Mark; Pohlmann, Paula; Rasco, Drew; Spira, Alexander; Tan, Antoinette; Wang, Ding; Ackerman, ... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A426 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study. (10th December 2020) Authors: Diab, Adi; Tykodi, Scott; Daniels, Gregory; Maio, Michele; Curti, Brendan; Lewis, Karl; Jang, Sekwon; Kalinka, Ewa; Puzanov, Igor; Spira, Alexander; Cho, Daniel; Guan, Shanhong; Puente, Erika; Hoch, Ute; Currie, Sue; Nguyen, Tuan; Lin, Wei; Tagliaferri, Mary; Zalevsky, Jonathan; Sznol, Mario Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study. (9th November 2020) Authors: Diab, Adi; Tykodi, Scott; Daniels, Gregory; Maio, Michele; Curti, Brendan; Lewis, Karl; Jang, Sekwon; Kalinka, Ewa; Puzanov, Igor; Spira, Alexander; Cho, Daniel; Guan, Shanhong; Puente, Erika; Hoch, Ute; Currie, Sue; Nguyen, Tuan; Lin, Wei; Tagliaferri, Mary; Zalevsky, Jonathan; Sznol, Mario Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A446 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Issue 4 (April 2015) Authors: Jimeno, Antonio; Bauman, Julie E.; Weissman, Charles; Adkins, Douglas; Schnadig, Ian; Beauregard, Patrice; Bowles, Daniel W.; Spira, Alexander; Levy, Benjamin; Seetharamu, Nagashree; Hausman, Diana; Walker, Luke; Rudin, Charles M.; Shirai, Keisuke Journal: Oral oncology Issue: Volume 51:Issue 4(2015:Apr.) Page Start: 383 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Amivantamab: A Potent Novel EGFR/c-MET Bispecific Antibody Therapy for EGFR-mutated Non-small Cell Lung Cancer. Issue 1 (2021) Authors: Guo, Matthew Z; Marrone, Kristen A; Spira, Alexander; Freeman, Kristine; Scott, Susan C Journal: Touch reviews in oncology & haematology Issue: Volume 17:Issue 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Issue 7 (11th December 2013) Authors: Stadler, Walter M.; Vaughn, David J.; Sonpavde, Guru; Vogelzang, Nicholas J.; Tagawa, Scott T.; Petrylak, Daniel P.; Rosen, Peter; Lin, Chia‐Chi; Mahoney, John; Modi, Sanjiv; Lee, Peter; Ernstoff, Marc S.; Su, Wu‐Chou; Spira, Alexander; Pilz, Korinna; Vinisko, Richard; Schloss, Charles; Fritsch, ... Journal: Cancer Issue: Volume 120:Issue 7(2014) Page Start: 976 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Issue 7 (11th December 2013) Authors: Stadler, Walter M.; Vaughn, David J.; Sonpavde, Guru; Vogelzang, Nicholas J.; Tagawa, Scott T.; Petrylak, Daniel P.; Rosen, Peter; Lin, Chia‐Chi; Mahoney, John; Modi, Sanjiv; Lee, Peter; Ernstoff, Marc S.; Su, Wu‐Chou; Spira, Alexander; Pilz, Korinna; Vinisko, Richard; Schloss, Charles; Fritsch, ... Journal: Cancer Issue: Volume 120:Issue 7(2014) Page Start: 976 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Issue 10030 (30th April 2016) Authors: Fehrenbacher, Louis; Spira, Alexander; Ballinger, Marcus; Kowanetz, Marcin; Vansteenkiste, Johan; Mazieres, Julien; Park, Keunchil; Smith, David; Artal-Cortes, Angel; Lewanski, Conrad; Braiteh, Fadi; Waterkamp, Daniel; He, Pei; Zou, Wei; Chen, Daniel S; Yi, Jing; Sandler, Alan; Rittmeyer, Achim Journal: Lancet Issue: Volume 387:Issue 10030(2016) Page Start: 1837 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network. (April 2022) Authors: Robert, Nicholas J.; Espirito, Janet L.; Chen, Liwei; Nwokeji, Esmond; Karhade, Mandar; Evangelist, Makenzi; Spira, Alexander; Neubauer, Marcus; Bullock, Susie; Walberg, Jennifer; Cheng, Steven K.; Coleman, Robert L. Journal: Lung cancer Issue: Volume 166(2022) Page Start: 197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗